drugset / Trial / NCT04734379
Rho Kinase (ROCK) Inhibitor in Tauopathies - 1
NaSingle-groupOpen-labelTreatment
Summary
A Phase 2a Open-Label Preliminary Safety, Tolerability, and Biomarker Study of Oral Fasudil in Patients with the 4-Repeat Tauopathies of Progressive Supranuclear Palsy-Richardson Syndrome or Corticobasal Syndrome
Timeline
- Start
- 2021-01-22
- Primary completion
- 2022-11-30
- Completion
- 2023-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fasudil | Small molecule | 180 mg | Oral |